Bowel cancer screening
Bowel cancer may be present for many years before a person shows symptoms, such as visible rectal bleeding, change in bowel habit, bowel obstruction, or anaemia. Often, symptoms such as these are not exhibited until the cancer has reached a relatively advanced stage. However, non-visible bleeding of the bowel may occur in the precancerous stages (Figure 1.1) for some time. The relatively slow development of most bowel cancers means that precancerous polyps and adenomas, and early-stage cancers, can potentially be screened for and treated. This makes bowel cancer a valid candidate for population screening (Standing Committee on Screening 2018).
An immunochemical faecal occult blood test (iFOBT) is a common method of bowel cancer screening (Schreuders et al. 2015). An iFOBT is a non-invasive test that can detect microscopic amounts of blood in a sample from a bowel motion, which may indicate a bowel abnormality, such as an adenoma or cancer.
National Bowel Cancer Screening Program
In Australia, government-funded, population-based bowel cancer screening has been available through the NBCSP since 2006. The NBCSP is funded and managed by the Australian Government Department of Health, Disability and Ageing and delivered through the National Cancer Screening Register (NCSR, November 2019 to present), with support from state and territory governments. The NBCSP aims to reduce the incidence of, and illness and mortality related to, bowel cancer in Australia through screening to detect cancers and pre-cancerous lesions in their early stages, when treatment will be most successful.
Target population
The NBCSP's target population list is compiled from those registered on a green Medicare card or a Department of Veterans' Affairs gold card.
The target population is informed by the National Health and Medical Research Council-endorsed Clinical practice guidelines for the prevention, early detection and management of colorectal cancer (guidelines). The Population Screening chapter of the guidelines was updated in 2023 to recommend that biennial iFOBT screening for the asymptomatic Australian population be offered from age 45 and continue to age 74 (previously 50–74) (CCACCSWP 2023). Since 1 July 2024, eligible people aged 45–49 have been able to request their first NBCSP kit from the program, or their doctor. The eligible 45–49 age group is not included in the performance indicator reporting in this report (which remains focused on the target 50–74 age group) but is reported separately. See Kit requests for those aged 45–49, July 2024 to December 2025.
Table 1.2 outlines the starting dates of each phase of the NBCSP and the target age groups.
Phase | Start date | Target ages (years) |
|---|---|---|
1 | 7 August 2006 | 55 and 65 |
2 | 1 July 2008(a) | 50, 55 and 65 |
2(b) | 1 July 2011 | 50, 55 and 65 |
3 | 1 July 2013 | 50, 55, 60 and 65 |
4 | 1 January 2015 | 50, 55, 60, 65, 70 and 74 |
4 | 1 January 2016 | 50, 55, 60, 64, 65, 70, 72 and 74 |
4 | 1 January 2017 | 50, 54, 55, 58, 60, 64, 68, 70, 72 and 74 |
4 | 1 January 2018 | 50, 54, 58, 60, 62, 64, 66, 68, 70, 72 and 74 |
4 | 1 January 2019 | 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72 and 74 |
5(c) | 1 July 2024 | 45–49 (eligible), 50–74 (target) |
- Eligible birth dates, and thus invitations, ended on 31 December 2010.
- Ongoing NBCSP funding commenced.
- People aged 45 to 49 can request their first bowel cancer screening kit. People aged 50 to 74 continue to receive a bowel cancer screening kit every 2 years.
Note: The eligible population for all Phase 2 and 3 start dates incorporates those turning the target ages from 1 January of that year, onwards.
To participate in the NBCSP, invitees complete the screening test and post completed samples to the NBCSP pathology laboratory for analysis. Results are sent to the participant, to the participant’s nominated primary health-care practitioner (PHCP), and to the NCSR. Participants with a positive screening result, indicated by blood in the stool sample, are advised to consult their PHCP to discuss further diagnostic assessment – in most cases, a colonoscopy.
The AIHW conducted a study of people diagnosed with bowel cancer between 2006 and 2008. This study showed that NBCSP invitees who had been diagnosed with bowel cancer through the program had a lower risk of dying from the disease and were more likely to have less advanced bowel cancers when diagnosed than non-invitees. These findings show that the NBCSP is contributing to reducing morbidity and mortality from bowel cancer in Australia (AIHW 2014a). More recent AIHW data linkage projects have further supported these findings (AIHW 2018a, 2018b).
For more information on the NBCSP, see the Department of Health, Disability and Ageing website.
Monitoring the NBCSP
NBCSP participant data come from a variety of sources along the screening pathway. Data are collected electronically, as well as through forms submitted by participants, PHCPs, colonoscopists, pathologists, and other medical staff returned to the NCSR. While health service organisations providing colonoscopy services are required to implement the Colonoscopy Clinical Care Standard (ACSQHC 2020), which includes reporting NBCSP patient results to the NCSR, is not mandated by the NBCSP, therefore these data may be incomplete.
This report is the eleventh to present national data for the NBCSP, using the current key performance indicators (PIs) developed by the National Bowel Cancer Screening Program Report and Indicator Working Group (Table 1). These indicators were endorsed by the Standing Committee on Screening in 2013 and the Community Care and Population Health Principal Committee under the auspice of the Australian Health Ministers’ Advisory Council in 2014 (AIHW 2014b). They are consistent with the 5 Australian Population Based Screening Framework steps: recruitment, screening, assessment, diagnosis, and outcomes (AIHW 2014b).
Current reporting limitations
Due to incomplete reporting to the NCSR by health-care providers, data – and results – for PIs 3 to 9 are not complete. In this report colonoscopy form and MBS claim data have been supplemented with Participant follow-up function (PFUF) data for those who had a positive screening test. See Improvements to the known colonoscopy count in Appendix A for further details.
Other limitations of NBCSP data include the lack of reliable population subgroup identification at the time of invitation. Within the 2023–2024 reporting period, NBCSP participants can self-identify as being an Aboriginal and/or Torres Strait Islander person, having a disability, or speaking a language other than English at home by completing and returning the participant details form along with their iFOBT for analysis. The NCSR uses self-reporting from the participant details form and the Medicare Voluntary Indigenous Identifier, along with other sources such as the National Cervical Screening Program (for invitees who participate in cervical screening) to assign Indigenous status. These sources are still not currently sufficient to reliably identify membership of these subgroups for all invitees. Hence, it is not possible to accurately determine NBCSP participation rates for these subgroups due to the lack of denominators (invitations issued). Ways to reduce these limitations are constantly being investigated; Equity in the NBCSP gives estimates of participation for these subgroups using proportions from the 2021 Census.
In the 2025 monitoring report, for the first time, NBCSP records were matched to cancer incidence data to 2021, allowing PI 6a (bowel cancer detection rate), PI 6b (PPV of diagnostic assessment for detecting bowel cancer), and PI 7 (interval cancer rate) to be reported. These data have not been revised in the 2026 monitoring report and match those reported in the previous report.
Four performance indicators remain aspirational, in that there is either a lack of national data or incomplete data. In this report, PI 5a (adenoma detection rate), PI 5b (positive predictive value, or PPV), of diagnostic assessment for detecting adenoma are not formally reported due to incomplete data. These indicators require complete data return from histopathology by health-care providers. Additionally, PI 8 (cancer clinico-pathological stage distribution) requires national cancer staging data, which is not currently available. Lastly, PI 9 (adverse events – hospital admission) requires linkage with complete national hospital admissions data, which is not currently performed. As the NCSR currently has (incomplete) information on adverse events, this will be used until a more complete adverse event data source becomes available.
Invitations to the target age group exclude those who do not have a valid mailing address in the NCSR. These individuals cannot be mailed, or may not receive, their NBCSP invitation which includes the kit until their Medicare address is updated. All users of Medicare are encouraged to update their address details when they move residence.
This is the sixth NBCSP monitoring report to use data extracted from the NCSR. The NCSR is a live database which is constantly being updated meaning later reports using data for the same time period may have a greater level of completeness.
ACSQHC (Australian Commission on Safety and Quality in Health Care) (2020) Colonoscopy Clinical Care Standard, Australian Commission on Safety and Quality in Health Care, Sydney, accessed 14 May 2025.
AIHW (2014a) Analysis of bowel cancer outcomes for the National Bowel Cancer Screening Program, AIHW, Australian Government, accessed 09 May 2022.
AIHW (2014b) Key performance indicators for the National Bowel Cancer Screening Program: technical report, AIHW, Australian Government, accessed 09 May 2022.
AIHW (2018a) Analysis of bowel cancer outcomes for the National Bowel Cancer Screening Program 2018, AIHW, Australian Government, accessed 09 May 2022.
AIHW (2018b) Analysis of cancer outcomes and screening behaviour for national cancer screening programs in Australia, AIHW, Australian Government, accessed 09 May 2022.
CCACCSWP (Cancer Council Australia Colorectal Cancer Screening Working Party) (2023). Clinical practice guidelines for the prevention, early detection and management of colorectal cancer: Population screening, Cancer Council Australia, Sydney, accessed 9 April 2024.
Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJY, Young GP and Kuipers EJ (2015) ‘Colorectal cancer screening: a global overview of existing programmes’, Gut, 64(10):1637–1649.
Standing Committee on Screening (2018) Population Based Screening Framework.
Report prepared for the Community Care and Population Health Principal Committee of the Australian Health Ministers’ Advisory Council, Department of Health, Australian Government, accessed 18 April 2023